TOPICAL COMPOSITIONS COMPRISING PEA PROTEINS AND POLYPHENOLS

Abstract

The object of the invention is topical compositions comprising pea proteins and polyphenols and the use thereof for the treatment of local or generalised disorders caused by increased permeation of the natural epithelial barriers. Said disorders may be of bacterial, viral, inflammatory, allergic and/or fungal origin, or endogenous or idiopathic.

Claims

1. Topical compositions comprising pea protein and polyphenols of the hydroxycinnamic and hydroxybenzoic acid families wherein the weight ratio of polyphenol to pea protein is from 0.4.1 to 1:10, in admixture with a suitable carrier.

2. Compositions according to claim 1 wherein the polyphenols are selected from ferulic acid, isoferulic acid, chlorogenic acid, ellagic acid, gallic acid and rosmarinic acid.

3. Compositions according to claim 2 wherein the polyphenols are selected from chlorogenic acid and ellagic acid.

4. Compositions according to claim 1, wherein the weight ratio of polyphenol to pea protein ranges from 1:1 to 1:6.

5. Compositions according to claim 4 wherein the weight ratio of polyphenol to pea protein is 1:1.

6. Compositions according to claim 1 in the form of ointments, lotions, creams, solutions, suspensions, gels, mouthwashes, medicated plasters or gauzes, powders or pessaries.

7. Compositions according to claim 1 further comprising moisturising, emollient, humectant, preservative, antioxidant or pH-regulating additives.

8. Compositions according to claim 7 wherein the additives are selected from lectin, lactic acid, sericin, poloxamers, carrageenan and arabinoxylan.

9. Compositions according to claim 8 wherein the additives are selected from lectin, poloxamers, carrageenan and arabinoxylan, each in concentrations by weight ranging from 0.1 to 2.5%.

10. Method of treating localised disorders of bacterial, viral, inflammatory, allergic and/or fungal, endogenous or idiopathic origin caused by permeation of the natural epithelial barriers, and disorders transferred from the epithelia to other systems in subjects in need thereof, said method comprising administering a pharmaceutical effective amount of the compositions of the claim 1 to said subjects.

11. The method according to claim 10, wherein said localized disorders comprise atopic dermatitis, rosacea, psoriasis, contact dermatitis, dermatitis caused by exposure to sunlight, radiotherapy or chemotherapy, cutaneous candidiasis, fungal infections, vaginal candidiasis, polybacterial vaginitis, fungal and bacterial infections of the skin and mucous membranes, and infections caused by protozoa.

Description

[0024] The examples below illustrate the invention in greater detail.

EXAMPLE 1

[0025] Cream formulation for cutaneous application (percentages by weight)

TABLE-US-00001 Ingredient % Pea protein 1.5%.sup.  Ferulic acid 1.5%.sup.  Sericin 2% Zanthoxylum b. extract 0.5%.sup.  Lactic acid 0.3%.sup.  Palmitate 6% Cocoa butter 1% Petrolatum 1% Dimethicone 2% Cetearyl alcohol 3% Propylene glycol 1% Glycerin 1% Disodium EDTA 0.2%.sup.  Phenoxyethanol 1% Dicetylphosphate 1% Water q.s. to 100

EXAMPLE 2

[0026] Cream formulation for cutaneous application (percentages by weight)

TABLE-US-00002 Ingredient % Pea protein 2.5%.sup.  Chlorogenic acid 2.5%.sup.  Sericin 2% Zanthoxylum b. extract 0.3%.sup.  Lectin 1% Palmitate 6% Cocoa butter 1% Petrolatum 1% Dimethicone 2% Cetearyl alcohol 3% Propylene glycol 1% Glycerin 1% Carrageenan 1% Disodium EDTA 0.2%.sup.  Phenoxyethanol 1% Dicetylphosphate 1% Water q.s. to 100

EXAMPLE 3

[0027] Cream formulation for vaginal application (percentages by weight)

TABLE-US-00003 Ingredient % Pea protein 2.5%.sup.  Ellagic acid 2.5%.sup.  Zanthoxylum b. extract 0.2%.sup.  Arabinoxylan 2% Lactic acid 0.4%.sup.  Poloxamer 2% Sericin 3% Squalane 2% Sodium bicarbonate 3% Salcare ® 4% Nipaguard ® 1% Water q.s. to 100

EXAMPLE 4

[0028] Cream formulation for vaginal application (percentages by weight)

TABLE-US-00004 Ingredient % Pea protein 2.5%.sup.  Gallic acid 2.5%.sup.  Poloxamer 5% Zanthoxylum b. extract 0.5%.sup.  Lactic acid 0.4%.sup.  Poloxamer 2% Sericin 3% Sodium bicarbonate 3% Salcare ® 4% Nipaguard ® 1% Carrageenan 1% Water q.s. to 100

EXAMPLE 5

[0029] Three cream formulations containing 5% by weight of the following mixtures: [0030] 1. 50% green coffee extract containing 45% chlorogenic acid and 50% pea protein; [0031] 2. 40% green coffee extract containing 45% chlorogenic acid and 60% pea protein; [0032] 3. 30% green coffee extract containing 45% chlorogenic acid and 70% pea protein,

[0033] were subjected to the permeability adhesion test (TEER) using murine fibroblasts L-929 which were infected with Staphylococcus aureus and Candida albicans strains.

[0034] Pre-treatment at various times with formulations 1-3 preserved the reduction in TEER induced by Candida (FIG. 1A) and the membrane integrity of fibroblasts infected with S. aureus (FIG. 1B).

[0035] Post-treatment increased TEER 6 and 24 hours after the Candida infection (FIG. 2A) and preserved membrane integrity to a time-dependent extent as from 6 hours after the S. aureus infection (FIG. 2B).

[0036] When the mixtures were administered simultaneously with the infection, loss of membrane integrity (FIG. 3A) in fibroblasts infected by Candida, and increased TEER in fibroblasts infected by S. aureus (FIG. 3B), were again limited.

EXAMPLE 6

[0037] Three cream formulations containing 5% by weight of the following mixtures:

[0038] 1. 50% pomegranate extract containing 40% ellagic acid and 50% pea protein;

[0039] 2. 40% pomegranate extract containing 40% ellagic acid and 60% pea protein;

[0040] 3. 30% pomegranate extract containing 40% ellagic acid and 70% pea protein,

[0041] were subjected to the permeability adhesion test (TEER) using a vaginal epithelium cell line VK2 E6/E7 (ATCC CRL-2616) which was infected with Gardnerella vaginalis (GV) and Candida albicans (CA) strains.

[0042] Pre-treatment at various times with formulations 1-3 preserved the membrane properties against CA and GV infection (FIGS. 4A and 4B).

[0043] Post-treatment preserved membrane integrity 6 and 24 hours after Candida infection (FIG. 5A and 5B).

[0044] When the mixtures were administered simultaneously with the infection, TEER increased in the infected cells (FIG. 6A and 6B).